Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2016-08-04 Interim / Quarterly Rep…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2016
2016-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 28, 2016, reporting the results of operations and financial condition for the quarter ended June 30, 2016. It mentions a press release and a conference call regarding quarterly results, which aligns with an Earnings Release. The document is relatively short (3247 characters) and includes a press release as an exhibit. The content focuses on announcing quarterly financial results rather than providing comprehensive financial statements or detailed analysis, which is typical for an Earnings Release. Therefore, the appropriate classification is Earnings Release (ER).
2016-07-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text includes an announcement of positive top-line results from a clinical study (FULFIL study) and references a press release filed as an exhibit. The document is short (3426 characters) and primarily serves to announce an event rather than provide detailed financial data or a full report. It does not contain financial statements or detailed analysis typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). It also does not fit into categories like Board/Management changes, M&A, or Capital updates. Given the nature of the filing and its content, it best fits the Regulatory Filings (RNS) category, which is a fallback for miscellaneous SEC filings that do not fit other specific categories.
2016-06-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 10, 2016, reporting on the entry into and termination of material definitive agreements related to office leases. It includes detailed descriptions of lease agreements and termination agreements, with references to exhibits to be filed with a future Form 10-Q. The content focuses on material contract events rather than financial results, management changes, or other report types. Form 8-K filings are current reports used to disclose significant events and are classified under Regulatory Filings (RNS) as they do not fit into other specific categories like Annual Report, Earnings Release, or Management Reports. The document length is 4623 characters, which is sufficient to contain substantive information rather than a mere announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-06-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about an accelerated plan to file a New Drug Application (NDA) by GlaxoSmithKline and Innoviva. The document is short (2802 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, audit information, management changes, or other detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-06-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 24, 2016, reporting "Other Events" related to a press release about clinical trial data for a drug. It includes no financial statements or detailed financial data but references a press release as an exhibit. The document is short (3726 characters) and primarily serves as an announcement of an event and the attached press release. It does not contain quarterly or annual financial results, management discussion, or audit information. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2016-05-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.